Skip to main content

Month: September 2020

Detailed information on the pre-emptive right of the former minority shareholders of ESO and Ignitis gamyba to acquire shares of Ignitis Group

AB Ignitis Grupė, (hereinafter – Ignitis Grupė or „the Company”) identification code 301844044, registered office placed at Žvejų str. 14, Vilnius, Republic of Lithuania. The total nominal value of issued bonds 900 000 000 EUR; ISIN codes XS1646530565; XS1853999313; XS2177349912.The Company received questions from former minority shareholders of Energijos Skirstymo Operatorius AB (hereinafter – ESO) and Ignitis Gamyba AB (hereinafter – Ignitis Gamyba) regarding the pre-emptive right to acquire shares of Ignitis grupė. In order to ensure that all former minority shareholders are equally informed, the Company publishes detailed information on the pre-emptive right to acquire shares of Ignitis grupė.I am a former minority shareholder of ESO and/or Ignitis Gamyba and have the pre-emptive rights to the shares of Ignitis grupė. How can I invest...

Continue reading

Detalizuota informacija apie buvusiems ESO ir „Ignitis gamybos“ smulkiesiems akcininkams taikomą pirmumo teisę įsigyti „Ignitis grupės“ akcijų

AB „Ignitis grupė“ (toliau – „Ignitis grupė“ ir Bendrovė), juridinio asmens kodas: 301844044, registruotos buveinės adresas: Žvejų g. 14, Vilnius. Bendra  „Ignitis grupė“ išleistų obligacijų nominali vertė 900 000 000 EUR; ISIN kodai: XS1646530565; XS1853999313; XS2177349912.Bendrovė sulaukė buvusių smulkiųjų AB „Energijos skirstymo operatorius“ (ESO) ir AB „Ignitis gamybos“ (GEN) akcininkų klausimų dėl pirmumo teisės įsigyti „Ignitis grupės“ akcijų. Siekdama užtikrinti, kad visi buvę smulkieji akcininkai būtų vienodai informuoti, Bendrovė skelbia detalizuotą informaciją apie pirmumo teisę įsigyti „Ignitis grupės“ akcijų.Žemiau pateikiami atsakymai į dažniausiai užduodamus klausimus apie šį procesą.Aš esu buvęs ESO ir/arba „Ignitis gamybos“ smulkusis akcininkas, kuris turi pirmumo teisę į „Ignitis grupės“ akcijas. Kaip galiu investuoti...

Continue reading

Sorrento Releases Preclinical Data for STI-1499 (COVI-Guard™) and STI-2020 (COVI-AMG™), Potent Neutralizing Antibodies Against SARS-CoV-2

In preclinical studies, both STI-1499 and STI-2020 demonstrated potent neutralizing activity against SARS-CoV-2 virus isolates, including the emerging Spike D614G variant virus.Both STI-1499 and STI-2020 demonstrated protective activities against SARS-CoV-2 infection in Syrian golden hamsters.At day 5, STI-2020 at 500 µg reduced virus load in hamster lungs to undetectable levels in 100% of animals tested, whereas STI-1499 at 2,000 µg reduced virus load below the detection limit in 60% of animals tested and showed a 10-fold reduction in the remaining 40% of animals.SAN DIEGO, Sept. 28, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) released preclinical data reporting on COVI-GUARD™ (STI-1499) and COVI-AMG™ (STI-2020; Affinity Matured COVI-Guard) neutralizing antibodies (nAbs) against SARS-CoV-2 as...

Continue reading

Unigold Inc. Announces Grant of Incentive Options

TORONTO, Sept. 28, 2020 (GLOBE NEWSWIRE) — Unigold Inc. Corp. (the “Company”) (TSXV: UGD) (FSE: UGD1) (OTCQX: UGDIF) announces that the Board of Directors has approved the grant of stock options (“Options”) to directors, officers, employees and consultants of the Company allowing for the acquisition of an aggregate of up to 6,000,000 common shares of the Company (“Shares”). An aggregate of 4,500,000 Options were issued with an exercise price of $0.34 per Share, with an expiry date of September 28, 2021. The remaining 1,500,000 Options were issued with an exercise price of $0.34 per Share and an expiry date of September 28, 2022. The grants of Options were issued pursuant and subject to the terms and conditions of the Company’s stock incentive plan and TSX Venture Exchange policies.About Unigold...

Continue reading

Stabilization period begins

Orphazyme A/SCompany announcement                                                                                       No. 56/2020                                                                                                         Company Registration No. 32266355      · Orphazyme A/S has today received notification regarding the beginning of the stabilization periodCopenhagen, Denmark, September 29, 2020 – With reference to company announcement no. 55/2020 dated September 29, 2020 regarding the pricing of the global offering (the “Global Offering”), consisting of an initial public offering of American Depositary Shares (the “ADSs”), each such ADS representing one ordinary share (the “Ordinary Shares”) of Orphazyme, on the Nasdaq Global Select Market in the United States under the symbol “ORPH” (the “U.S....

Continue reading

JUPITER-02 Phase III Global Study of Toripalimab at the Interim Analysis Met Pre-Specified Primary Endpoint of Progression-Free Survival in Recurrent or Metastatic Nasopharyngeal Carcinoma

SHANGHAI, China, Sept. 28, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that an Independent Monitoring Committee (IDMC) determined that the randomized, double-blind, placebo-controlled, international multi-center Phase III study JUPITER-02 at the interim analysis had met its pre-specified primary endpoint. The results of the study showed that Toripalimab in combination with Gemcitabine/Cisplatin as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) significantly extended the progression-free survival than the current standard treatment of Gemcitabine/Cisplatin. The Company will submit biologic license application...

Continue reading

Orphazyme prices its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe

Orphazyme A/SCompany announcement                                                                                           No. 55/2020                                                                                                          Company Registration No. 32266355As announced on September 21, 2020, Orphazyme commenced an initial public offering of American Depositary Shares (“ADSs”) in the United States, and commenced a concurrent private placement of ordinary shares in Europe Today, September 29, 2020 (CET), Orphazyme announces the pricing of the global offering at a price per new ordinary share of DKK 70.1844, corresponding to a price of USD 11.00 per ADS The aggregate gross proceeds from the global offering will amount to approximately DKK 534,534,637 (USD 83,777,606 using a DKK/USD exchange rate of 6.3804) (assuming no exercise...

Continue reading

Mueller Water Products to Participate in the 2020 RBC Capital Markets Future of Water Virtual Conference

ATLANTA, Sept. 28, 2020 (GLOBE NEWSWIRE) — Mueller Water Products, Inc. (NYSE: MWA) will participate in the 2020 RBC Capital Markets Future of Water Virtual Conference on Tuesday, September 29, 2020. The panel discussion is currently scheduled to take place at 8:40 a.m. ET. A live webcast, audio replay and any changes to the presentation timing will be available on the Investor Relations section of the Company’s website www.muellerwaterproducts.com. A replay of the webcast will be available for approximately 90 days.About Mueller Water Products, Inc.Mueller Water Products, Inc. (NYSE: MWA) is a leading manufacturer and marketer of products and services used in the transmission, distribution and measurement of water in North America. Our broad product and service portfolio includes engineered valves, fire hydrants, pipe connection...

Continue reading

Coastal Financial Corporation earns Piper Sandler Sm-All Stars Class of 2020 award

EVERETT, Wash., Sept. 28, 2020 (GLOBE NEWSWIRE) — Coastal Financial Corporation (NASDAQ: CCB), the parent company of Coastal Community Bank, has been named to the Piper Sandler Bank & Thrift Sm-All Class of 2020.This award puts Coastal among an elite group of small-cap banks and thrifts in the U.S and is presented as a testament to its hard work and successful management of the business. Coastal scored well versus its peers based on several key metrics, including growth trends, profitability, asset quality, and capital.“To earn the Piper Sandler Sm-All Star award for a second year is a huge honor,” said Eric Sprink, President & CEO, Coastal Financial Corporation. “As we all know, this year has been challenging. Our employees are essential workers and they have gone above and beyond adjusting to this new working environment...

Continue reading

Millrock Reports Update on Drilling, 64North Gold Project, Alaska

VANCOUVER, British Columbia, Sept. 28, 2020 (GLOBE NEWSWIRE) — Millrock Resources Inc. (TSX-V: MRO, OTCQB: MLRKF) (“Millrock” or the “Company”) reports assay results from drilling from exploration drill holes 20EC05, 20RE06 and 20AU07 that have been recently completed at the Echo, Resolution, and Aurora targets on the West Pogo block of the 64North Gold project.The locations of the holes drilled so far this year on the West Pogo Block are shown in Figure 1, along with the locations of the Echo, Reflection, and Aurora target areas. Also depicted are the locations of the Pogo Mine and the Goodpaster deposit situated on claims owned by Northern Star Resource Ltd (“Northern Star”). Northern Star recently indicated that it intends to perform delineation drilling at Goodpaster with a $21 million budget in the coming year,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.